With strong ties to Dartmouth College and relevant areas of industry, Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. The firm partners with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery to profitability. With robust funding options, a diverse and high impact Programmatic pipeline, partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health. Examples of programs: scleroderma diagnostics; cellular therapy for cancer; anti-inflammatory therapy; myocardial infarction therapy; atherosclerosis therapy. In January 2015 Cardio3 BioSciences SA (cell therapies) acquired OnCyte LLC (immuno-oncology) from Celdara Medical LLC for $182mm including earn-outs.